The pharmacokinetics of metronidazole was evaluated in eight patients with alcoholic liver disease. Metronidazole (7.5 mg/kg) was administered to each patient intravenously. Serial blood samples were obtained after the dose. Serum metronidazole concentrations were determined by high-performance liquid chromatography. The following pharmacokinetic parameters (mean standard deviations) were obtained: half-life, 18.31 6.06 h; elimination rate constant, 0.042 0.013 h-'; volume of distribution, 0.77 0.16 liters/kg; and total body clearance, 0.51 0.11 mIl/min per kg. Compared with subjects with normal liver function, patients with liver disease showed a reduction in drug elimination rate and total body clearance. The half-life of metronizadole in serum and volume of distribution were increased. Large variations of these parameters were also observed among the patients. Oil the basis of these observations, a reduced dose of metronidazole should be given to patients with alcoholic liver disease to avoid accumulation of metronidazole and its metabolites.
Metronidazole, a 5-nitroimidazole derivative, is effective against most anaerobic bacteria, including Bacteroides fragilis (2, 8) . The use of metronidazole in clinical practice has increased substantially since its role in the treatment of anaerobic infections was recognized.
The drug is primarily metabolized by the liver to form two oxidative metabolites: 1-(2-hydroxyethyl)-2-hydroxymethylary to drug accumulation. An adequate knowledge of the disposition of the drug is necessary to optimize therapy in these patients.
This study was performed to evaluate the pharmacokinetics of metronidazole in patients with alcoholic liver disease. Results were used as the basis for development of dosage guidelines for these patients. 5-nitroimidazole (hydroxy metabolite) and 1-acetic acid-2-methyl-5-nitroimidazole (acid metabolite) (7) . The reduction of liver function is expected to impair the production of the metabolites, thus delaying elimination and resulting in accumulation of the parent drug. Dosage adjustment may therefore be needed to avoid potential undesired effects second-* Corresponding author. (9) . The coefficients of variations of the assay results were between 2 and 8%.
Pharmacokinetic parameters of metronidazole and its metabolites were determined by noncompartmental kinetic analysis. The elimination rate constant was determined by linear least-square regression analysis of the elimination phase of the concentration-time curve after semilogarithmic transformation. Half-life was calculated by dividing the natural logarithm of 2 by the elimination rate constant. The area under the concentration-time curve was determined by using the trapezoidal rule with extrapolation to infinity. The volume of distribution was calculated by dividing the dose by the product of the area under the concentration-time curve times the elimination rate constant. The total body clearance was obtained by multiplying the elimination rate constant by the volume of distribution.
RESULTS
Eight patients participated in the study. The ages and weights (mean ± standard deviation [SD]) of the patients were 52.0 + 12.6 years and 74.5 + 19.6 kg, respectively. All of the patients had alcoholic liver disease, and five of them had biopsy-proven cirrhosis. All of the patients had ascites, four had esophageal varices, and two had histories of encephalopathy.
The pharmacokinetic parameters of metronidazole are listed in Table 2 . The half-life of the drug (mean + SD) was 18.31 + 6.06 h, and the volume of distribution (mean + SD) was 0.77 + 0.16 liters/kg. The hydroxy metabolite was detectable in only five patients. The calculated pharmacokinetic parameters of the metabolites are tabulated in Table 3 . The acetic acid metabolite was not detectable in any of the serum samples collected. Figure 1 represents a typical concentration profile of the parent drug in serum and the appearance of the hydroxy metabolite. Also presented in Fig. 1 is the concentration profile derived from serum samples from normal subjects based on the mean pharmacokinetic parameters in serum obtained from nine individuals with normal liver function.
None of the patients experienced any adverse effect secondary to metronidazole during the study period.
DISCUSSION
The elimination of metronidazole was found to be impaired in patients with alcoholic liver disease. The mean elimination half-life was 18.31 h, which was substantially higher than the mean of 8 h observed in normal subjects by our group. The mean volume of distribution of 0.77 liters/kg was again higher than the 0.55 liters/kg observed in normal subjects. The reduced systemic drug clearance, therefore, reflected the net effects of decreased elimination rate and increased volume of distribution.
Compared with subjects with normal liver function, patients with liver disease showed an impaired production of metabolites. In three of the patients, the concentration of the hydroxy metabolite in plasma was below the detectable limit. In the other five patients, the mean peak concentration of the hydroxy metabolite was lower and the time needed to attain such peak concentration was longer than times observed in normal subjects (3) . A defect in oxidative metabolism may be responsible for the reduced metabolite production.
A substantial amount of variability in the kinetic parameters was observed among the patients. A threefold difference in the elimination half-lives was present in our patients. In a study conducted by Daneshmend et al., the authors reported that the mean half-life in serum was 10.8 h in six cirrhotic patients (1), in contrast with the mean half-life of 18.3 h reported in our study. These observed differences in drug elimination rates may reflect the spectrum of liver impairment among patients. In addition, the differences in the amounts of ascites in our patients may be responsible for the substantial variability seen in the metronidazole volume of distribution. Such large variations in pharmacokinetic parameters were not unique to this patient group. Similar observations were reported for metronidazole in hospitalized patients who had normal liver and kidney functions (4) . The heterogeneity of disease states, body composition, fluid balance, and hemodynamics, as well as nutritional status, may affect the disposition of the drug.
In view of these drastic changes in metronidazole pharmacokinetics in patients with liver dysfunction, appropriate dosage reduction should be done to avoid accumulation of parent drug and metabolites. The usual recommended dose of metronidazole is 500 mg to be given every 6 h; Fig. 2 is a simulation of the drug concentration in serum when such dosage is administered to a patient with liver dysfunction, according to the mean pharmacokinetic parameters obtained from this study. The concentration profile when the drug is given to a normal subject is also presented, on the basis of the mean pharmacokinetic parameters obtained in nine normal volunteers. The simulation revealed a steady-state metronidazole concentration in the range of 30 to 40 p.g/ml, which is higher than the therapeutic concentration of 15 to 25 .g/ml commonly maintained in patients with normal liver function (5). The MICs of metronidazole against most clinically important anaerobes are usually less than 4 ,ug/ml (5) . Concentrations in serum in the 30-to 40-,Ig/ml range are not expected to yield additional therapeutic benefit for most patients; however, some patients may experience an in- creased incidence of adverse reactions because of the extra drug exposure and metabolite accumulation. Mental confusion had indeed been reported in a patient with a serum metronidazole concentration of >40 ,ug/ml (6) . The mean systemic clearance of the drug was reduced to about 62% in our patients with liver dysfunction; the recommended dosage should therefore be reduced accordingly. Since the mean half-life was prolonged to about 18 h, the frequency of drug administration can be prolonged. A 12-h dosing regimen, instead of the 6-h regimen usually recommended, will result in cost savings because of the reduced drug preparation expenses and personnel time. However, the clinician should be aware of the differences of drug disposition among the patients; the dosing regimen should therefore be individualized, and monitoring of the drug concentration in serum may be necessary to optimize therapy in this special group of patients.
